4-叔丁基-1-环己烯硼酸 | 850567-91-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 硼酸衍生物
• 中文名称: 4-叔丁基-1-环己烯硼酸
• 中文别名: 4-叔丁基环己烯-1-基硼酸
• 英文名称: 4-tert-butylcyclohex-1-en-1-ylboronic acid
• 英文别名: (4-(tert-Butyl)cyclohex-1-en-1-yl)boronic acid；(4-tert-butylcyclohexen-1-yl)boronic acid
• CAS: 850567-91-8
• 化学式: C₁₀H₁₉BO₂
• mdl: MFCD06659856
• 分子量: 182.071
• InChiKey: QPJWLDFYBBQYSG-UHFFFAOYSA-N

物化性质

• 熔点：
  166-170℃
• 沸点：
  296.1±33.0 °C(Predicted)
• 密度：
  0.97±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.45
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-t-Butylcyclohexen-1-ylboronic acid
Synonyms: 4-tert-Butyl-1-cyclohexen-1-ylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H319: Causes serious eye irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-t-Butylcyclohexen-1-ylboronic acid
CAS number: 850567-91-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H19BO2
Molecular weight: 182.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-叔丁基-1-环己烯硼酸 在 盐酸 、 草酰氯 、 二氯双(三邻甲苯膦)合钯(II) 、 甲基磺酰胺 、 AD-mix β 、 水 、 sodium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 lithium hydroxide 、 lithium hexamethyldisilazane 、 亚磷酸三乙酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 叔丁醇 为溶剂， 反应 104.58h， 生成 sodium 2-{4-[2-[4-(4-(R)-tert-butylcyclohex-1-enyl)phenyl]-2-(4'-chloro-2'-methylbiphenyl-4-ylcarbamoyl)ethyl]benzoylamino}ethanesulfonate
  参考文献：
  名称：

  [EN] GLUCAGON ANTAGONISTS
  [FR] ANTAGONISTES DU GLUCAGON

  摘要：

  本文提供了化合物，包括其对映体纯形式，以及具有胰高血糖素受体拮抗剂或逆向激动剂活性的药用盐或共晶体及前药。此外，本文提供了包括这些化合物的药物组合物，以及治疗、预防、延缓发病时间或减少一种或多种胰高血糖素受体拮抗剂适用的疾病或症状的发展或进展风险的方法，包括I型和II型糖尿病、胰岛素抵抗和高血糖。此外，本文提供了制备或生产本文披露的化合物的方法，包括其对映体纯形式，以及药用盐或共晶体及前药。

  公开号：

  WO2015191900A1
• 作为产物：
  描述：

  4-tert-butylcyclohexanone tosylhydrazone 在 sodium periodate 、 正丁基锂 、 四甲基乙二胺 、 ammonium acetate 、 水 作用下， 以 正己烷 、 丙酮 为溶剂， 反应 3.0h， 生成 4-叔丁基-1-环己烯硼酸
  参考文献：
  名称：

  铜催化的烯基硼酸的三或四官能度制备四氢咔唑-1-酮和吲哚[2,3-a]咔唑

  摘要：

  我们描述了烯基硼酸的三或四官能化的级联策略，以制备具有N的高收率的各种四氢咔唑-1-酮和吲哚[2,3- a ]咔唑-羟基苯并三嗪-4-酮（HOOBT）和芳基肼分别作为氧和氮源。机理研究表明，多米诺反应在一锅法反应中经过五个步骤，经历了铜催化的Chan-Lam反应，[2,3]重排，亲核取代，氧化和顺序[3,3]重排。该反应显示出广泛的底物范围，并且可以耐受多种官能团。更重要的是，该反应易于以克为单位进行，并且产物可以通过简单的萃取，洗涤和重结晶进行纯化，而无需快速柱色谱。本协议的特点是易于获得的起始原料，高位标记的功能化，一锅中的五步串联，多个C–C / C–O / C–N键形成以及吲哚图案的多样性。

  DOI：

  10.1039/d0gc01514h

文献信息

• [EN] GLUCAGON ANTAGONISTS<br/>[FR] ANTAGONISTES DE GLUCAGON
  申请人：METABASIS THERAPEUTICS INC

  公开号：WO2010019830A1

  公开（公告）日：2010-02-18

  Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co- crystals and prodrugs thereof. Formula I

  本文提供了化合物，包括其对映体纯形式，以及具有胰高血糖素受体拮抗剂或逆向激动剂活性的药用盐或共晶体和前药。此外，本文提供了包括这些化合物的药物组合物，以及治疗、预防、延缓发病时间或减少一种或多种胰高血糖素受体拮抗剂适用的疾病或病情的发展或进展风险的方法，包括I型和II型糖尿病、胰岛素抵抗和高血糖。此外，本文提供了制备或生产本文披露的化合物的方法，包括其对映体纯形式，以及药用盐或共晶体和前药。公式I
• [EN] PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] DÉRIVÉS DE L'ACIDE PYRIDIN-3-YL-ACÉTIQUE UTILISÉS COMME INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：VIIV HEALTHCARE UK (NO 5) LTD

  公开号：WO2017006280A1

  公开（公告）日：2017-01-12

  Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS. (I)

  披露了公式I的化合物，包括药物可接受的盐、包含这些化合物的药物组合物、制造这些化合物的方法以及它们在抑制HIV整合酶和治疗感染HIV或艾滋病的人的使用。
• Synthesis of α-oxygenated ketones and substituted catechols via the rearrangement of N-enoxy- and N-aryloxyphthalimides
  作者：Michelle A. Kroc、Aditi Patil、Anthony Carlos、Josiah Ballantine、Stephanie Aguilar、Dong-Liang Mo、Heng-Yen Wang、Daniel S. Mueller、Donald J. Wink、Laura L. Anderson

  DOI：10.1016/j.tet.2017.01.061

  日期：2017.7

  synthesis of α-oxygenated carbonyl compounds and catechols is the treatment of a carbonyl compound or a phenol with an electrophilic oxygen source. As an alternative approach to these important structures, formal [3,3]-rearrangements of N-enoxyphthalimides, N-enoxyisoindolinones, and N-aryloxyphthalimides have been explored. When used in combination with an initial Chan-Lam coupling, these transformations

  合成α-氧化羰基化合物和邻苯二酚的常用方法是用亲电子氧源处理羰基化合物或苯酚。作为这些重要结构的替代方法，已经研究了N-烯氧基邻苯二甲酰亚胺，N-烯氧基异吲哚满酮和N-芳氧基邻苯二甲酰亚胺的形式[3,3]重排。当与初始Chan-Lam偶联结合使用时，这些转化有助于烯基硼酸的双氧合以合成α-加氧的酮和芳基硼酸的双氧合以合成儿茶酚。N-烯氧基异吲哚啉酮的重排也已显示为非对映选择性的。
• Preparation of α-Oxygenated Ketones by the Dioxygenation of Alkenyl Boronic Acids
  作者：Aditi S. Patil、Dong-Liang Mo、Heng-Yen Wang、Daniel S. Mueller、Laura L. Anderson

  DOI：10.1002/anie.201202704

  日期：2012.7.27

  Two in two: Dioxygenation of alkenyl boronic acids has been achieved with N‐hydroxyphthalimide. The two‐step process involves etherification of an alkenyl boronic acid with N‐hydroxyphthalimide followed by a [3,3] rearrangement. The dioxygenated product can then be hydrolyzed to form either the corresponding α‐hydroxy ketone or the α‐benzoyloxy ketone.

  二分之二：N-羟基邻苯二甲酰亚胺已实现了烯基硼酸的双加氧反应。分两步进行，涉及烯基硼酸与N-羟基邻苯二甲酰亚胺的醚化，然后进行[3,3]重排。然后可以将双加氧产物水解形成相应的α-羟基酮或α-苯甲酰氧基酮。
• Preparation and Rearrangement of <i>N</i>-Vinyl Nitrones: Synthesis of Spiroisoxazolines and Fluorene-Tethered Isoxazoles
  作者：Dong-Liang Mo、Donald A. Wink、Laura L. Anderson

  DOI：10.1021/ol3022885

  日期：2012.10.19

  N-Vinyl nitrones derived from fluorenone have been prepared via a copper-mediated coupling between fluorenone oxime and vinyl boronic acids. These compounds undergo subsequent rearrangement and addition reactions that are distinct from the traditional [3 + 2] cycloaddition reactivity of nitrones. Thermal rearrangements of fluorenone N-vinyl nitrones give spiroisoxazolines, while treatment with alkynes

  经由芴酮肟和乙烯基硼酸之间的铜介导的偶联，制备了衍生自芴酮的N-乙烯基硝酮。这些化合物会经历随后的重排和加成反应，这不同于传统的硝酮的[3 + 2]环加成反应性。芴酮N-乙烯基硝酮的热重排生成螺异恶唑啉，而用炔烃处理则得到芴系的异恶唑。讨论了芴酮N-乙烯基硝酮的制备及其局限性及其后续的重排和加成反应。